(Q40632310)

22 September 2017

title

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers (English)

1 reference

22 September 2017

L E Rothuizen

1

1 reference

22 September 2017

T Buclin

2

1 reference

22 September 2017

F Spertini

3

1 reference

22 September 2017

I Trinchard

4

1 reference

22 September 2017

A Munafo

5

1 reference

22 September 2017

P A Buchwalder

6

1 reference

22 September 2017

A Ythier

7

1 reference

22 September 2017

J Biollaz

8

1 reference

22 September 2017

publication date

1 September 1999

1 reference

Journal of Neuroimmunology

22 September 2017

published in

1 reference

22 September 2017

volume

99

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

131-141

1 reference

Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Interferon beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Correlation between interferon production and clinical disease activity in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Circulating adhesion molecules and inflammatory mediators in demyelination: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Distinct STAT structure promotes interaction of STAT2 with the p48 subunit of the interferon-alpha-stimulated transcription factor ISGF3

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Recombinant Interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

The Effects of Various Cytokines on Interleukin-6 and Interferon-α Synthesis in Human Peripheral Blood Mononuclear Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Management of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Pretreatment of astrocytes with interferon-alpha/beta prevents neuronal mitochondrial respiratory chain damage.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Clinical toxicity of the interferons.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Prescribing recommendations for interferon-Beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

Highly sensitive enzyme immunoassay of human interferon-beta 1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900029-6

7 January 2021

10.1016/S0165-5728(99)00029-6

Identifiers

DOI

1 reference

22 September 2017

1 reference